AbbVie (ABBV) Interest Expenses (2012 - 2026)
AbbVie (ABBV) posted quarterly Interest Expenses of $717.0 million for Q1 2026, up 2.43% year-over-year from $700.0 million in Q1 2025, and little changed quarter-over-quarter from $714.0 million in Q4 2025.
AbbVie (ABBV) Interest Expenses (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Interest Expenses for 15 consecutive years, with $717.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 2.43% year-over-year to $717.0 million; the TTM figure through Mar 2026 stood at $2.9 billion (up 2.07% YoY), while the FY2025 annual figure was $15.0 billion, up 1.32% from the prior year.
- Interest Expenses steadied at $717.0 million in Q1 2026 per ABBV's latest filing, from $714.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $882.0 million in Q4 2022 and bottomed at $548.0 million in Q1 2022.
- Historically, Interest Expenses has averaged $658.3 million across 5 years, with a median of $700.0 million in 2025.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 52.07% — and 2023, when it slumped 36.05%.
- AbbVie's Interest Expenses stood at $882.0 million in 2022, then tumbled by 36.05% to $564.0 million in 2023, then climbed by 25.0% to $705.0 million in 2024, then grew by 1.28% to $714.0 million in 2025, then rose by 0.42% to $717.0 million in 2026.
- Business Quant data shows ABBV's Interest Expenses at $717.0 million in Q1 2026, $714.0 million in Q4 2025, and $739.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 746.00 Mn |
| Jun 30, 2026 | 746.00 Mn |
| Mar 31, 2026 | 717.00 Mn |
| Mar 31, 2026 | 717.00 Mn |
| Dec 31, 2025 | 714.00 Mn |
| Dec 31, 2025 | 714.00 Mn |
| Sep 30, 2025 | 739.00 Mn |
| Sep 30, 2025 | 739.00 Mn |
| Jun 30, 2025 | 740.00 Mn |
| Jun 30, 2025 | 740.00 Mn |
| Mar 31, 2025 | 700.00 Mn |
| Mar 31, 2025 | 700.00 Mn |
| Dec 31, 2024 | 705.00 Mn |
| Dec 31, 2024 | 705.00 Mn |
| Sep 30, 2024 | 720.00 Mn |
| Sep 30, 2024 | 720.00 Mn |
| Jun 30, 2024 | 726.00 Mn |
| Jun 30, 2024 | 726.00 Mn |
| Mar 31, 2024 | 660.00 Mn |
| Mar 31, 2024 | 660.00 Mn |